L'intérêt à découvert pour Chime Financial donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Chime Financial. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Chime Financial (NASDAQ:CHYM) Stock, Rapport sur les intérêts à découvert

Chime Financial Inc is a financial technology company that believes in core banking services.

Chime Financial, Inc. - Class A Common Stock

Chime Financial Inc

CAHYA MATA SARAWAK BHD by Cahya Mata Sarawak Bhd

Cahya Mata Sarawak Bhd

Throughout the last three months, 8 analysts have evaluated Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $4.69, a high estimate of $8.00, and a low estimate of $1.50. Observing a downward trend, the current average is 23.99% lower than the prior average price target of $6.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1751976144_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Canaan is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$1.50</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$2.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Announces</td>
<td>Buy</td>
<td>$3.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Canaan. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Canaan compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Canaan's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Canaan's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CAN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Canaan analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Canaan</h2>
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
<h3>Key Indicators: Canaan's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Canaan's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 135.89% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -104.42%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Canaan's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -33.84%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Canaan's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -16.81%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 0.94, Canaan faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Canaan: 8 Analysts Share Their Views

News

HUMA

Humacyte Announces Symvess Has Been Awarded  Electronic Catalog Listing Approval From US Defense Logistics Agency

Biotech

General

Johnson & Johnson Announces Submission Of A Supplemental New Drug Application To U.S. FDA Based Upon Long-term Data Evaluating The Safety And Efficacy Of Caplyta For The Prevention Of Relapse In Schizophrenia

In the latest quarter, 4 analysts provided ratings for BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $19.5, a high estimate of $28.00, and a low estimate of $12.00. Surpassing the previous average price target of $17.00, the current average has increased by 14.71%.
<img src="https://www.benzinga.com/files/images/story/2025/1751976129_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of BlackSky Technology among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Austin Moeller</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Josh Sullivan</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Austin Moeller</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$12.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to BlackSky Technology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of BlackSky Technology compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of BlackSky Technology's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of BlackSky Technology's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BKSY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BlackSky Technology analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering BlackSky Technology: A Closer Look</h2>
BlackSky Technology Inc is a provider of real-time geospatial intelligence. The company delivers on-demand, high-frequency imagery, monitoring, and analytics of some of the critical and strategic locations, economic assets, and events in the world. It designs, owns, and operates one of the industry's low earth orbit (LEO) small satellite constellations, optimized to capture imagery cost-efficiently where and when its customers need it. its Spectra AI software platform processes data from BlackSky's constellation and other third-party sensors to develop the critical insights and analytics that provide its customers with the actionable intelligence. Geographically, the company operates in North America, the Middle East, Asia, and Others.
<h3>BlackSky Technology: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, BlackSky Technology showcased positive performance, achieving a revenue growth rate of 21.9% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: BlackSky Technology's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -43.37%, the company may face hurdles in effective cost management.
Return on Equity (ROE): BlackSky Technology's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -14.02%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -4.75%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: BlackSky Technology's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.39, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BlackSky Technology Inc. Class A Common Stock

BKSY

Deep Dive Into BlackSky Technology Stock: Analyst Perspectives (4 Ratings)

Throughout the last three months, 17 analysts have evaluated Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $7.99, a high estimate of $15.00, and a low estimate of $0.01. A decline of 21.59% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1751976115_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Sunrun. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Christopher Dendrinos</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$5.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Sophie Karp</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Underweight</td>
<td>$6.00</td>
<td>-</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Maintains</td>
<td>Sell</td>
<td>$0.01</td>
<td>$0.01</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Christopher Dendrinos</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Maheep Mandloi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Maintains</td>
<td>Hold</td>
<td>$7.78</td>
<td>$7.78</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$4.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Christopher Dendrinos</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Vikram Bagri</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sunrun. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sunrun compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Sunrun's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Sunrun's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RUN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sunrun analyst ratings.</a>
<h2>Get to Know Sunrun Better</h2>
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
<h3>Sunrun: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Sunrun's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 10.06%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.92%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Sunrun's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.93%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Sunrun's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.25%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Sunrun's debt-to-equity ratio is notably higher than the industry average. With a ratio of 5.23, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Sunrun Through 17 Analysts

In the preceding three months, 4 analysts have released ratings for BrightSpire Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRSP#NYSE">BRSP</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $6.12, a high estimate of $6.50, and a low estimate of $5.00. Observing a downward trend, the current average is 13.31% lower than the prior average price target of $7.06. 
<img src="https://www.benzinga.com/files/images/story/2025/1751976096_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive BrightSpire Capital. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terry Ma</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Jason Weaver</td>
<td>Jones Trading</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.50</td>
<td>$6.50</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$6.50</td>
<td>$7.50</td>
</tr>
<tr>
<td>Jason Weaver</td>
<td>Jones Trading</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.50</td>
<td>$7.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to BrightSpire Capital. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of BrightSpire Capital compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of BrightSpire Capital's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of BrightSpire Capital's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BRSP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BrightSpire Capital analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind BrightSpire Capital</h2>
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
<h3>BrightSpire Capital's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3M period, BrightSpire Capital faced challenges, resulting in a decline of approximately -19.13% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: BrightSpire Capital's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 6.5%, the company may face hurdles in effective cost management.
Return on Equity (ROE): BrightSpire Capital's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.47%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): BrightSpire Capital's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.13%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 2.29.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRSP

BrightSpire Capital Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

In the latest quarter, 14 analysts provided ratings for Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $108.0, a high estimate of $112.00, and a low estimate of $100.00. This current average represents a 2.83% decrease from the previous average price target of $111.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1751976086_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Merit Medical Systems's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$108.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$112.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$111.00</td>
<td>$111.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Merit Medical Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Merit Medical Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Merit Medical Systems's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Merit Medical Systems analyst ratings.</a>
<h2>Discovering Merit Medical Systems: A Closer Look</h2>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
<h3>Merit Medical Systems's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Merit Medical Systems displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 9.84%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.48%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Merit Medical Systems's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.15%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Merit Medical Systems's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.23% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.57, Merit Medical Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MMSI

What 14 Analyst Ratings Have To Say About Merit Medical Systems

In the preceding three months, 15 analysts have released ratings for SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">3</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $12.68, along with a high estimate of $20.00 and a low estimate of $5.00. Observing a downward trend, the current average is 5.65% lower than the prior average price target of $13.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1751976075_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of SolarEdge Technologies among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sophie Karp</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Underweight</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Maintains</td>
<td>Sell</td>
<td>$6.90</td>
<td>$6.90</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Maheep Mandloi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Maintains</td>
<td>Hold</td>
<td>$6.90</td>
<td>$6.90</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Raises</td>
<td>Sell</td>
<td>$6.90</td>
<td>$3.90</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Austin Moeller</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$16.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Sell</td>
<td>$5.00</td>
<td>-</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to SolarEdge Technologies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SolarEdge Technologies compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into SolarEdge Technologies's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SEDG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on SolarEdge Technologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know SolarEdge Technologies Better</h2>
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.
<h3>Breaking Down SolarEdge Technologies's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, SolarEdge Technologies showcased positive performance, achieving a revenue growth rate of 7.38% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -44.89%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): SolarEdge Technologies's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -15.73%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): SolarEdge Technologies's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -3.82%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: SolarEdge Technologies's debt-to-equity ratio stands notably higher than the industry average, reaching 1.28. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SEDG

Deep Dive Into SolarEdge Technologies Stock: Analyst Perspectives (15 Ratings)

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday.
Shares of Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) fell sharply in today's <a href="https://www.benzinga.com/quote/HSDT">pre-market trading</a>.
Helius Medical Technologies filed prospectus for $25 million share offering.
Helius Medical Technologies shares dipped 10.9% to $8.42 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Blue Gold Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGL#NASDAQ">BGL</a>) shares tumbled 15.6% to $63.00 in pre-market trading after dipping 30% on Monday.</li>
<li>Pelthos Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHS#NASDAQ">PTHS</a>) dipped 8.3% to $23.79 in pre-market trading after gaining 60% on Monday.</li>
<li>AirJoule Technologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRJ#NASDAQ">AIRJ</a>) fell 5.8% to $4.82 in pre-market trading.</li>
<li>Aebi Schmidt Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEBI#NASDAQ">AEBI</a>) dipped 5.2% to $11.50 in pre-market trading after falling more than 10% on Monday.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) shares declined 5.1% to $25.08 in pre-market trading after declining 4% on Monday. Keybanc analyst Sophie Karp upgraded SolarEdge Technologies from Underweight to Sector Weight.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares slipped 4.8% to $10.58 in pre-market trading after gaining more than 5% on Monday. Keybanc analyst Sophie Karp upgraded Sunrun from Underweight to Sector Weight.</li>
<li>Shoals Technologies Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) fell 4% to $6.05 in pre-market trading after gaining 5% on Monday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46289573/trump-tariffs-sink-dow-over-400-points-investor-sentiment-declines-but-fear-greed-index-remains-in-extreme-greed-zone">Trump Tariffs Sink Dow Over 400 Points: Investor Sentiment Declines, But Fear &amp; Greed Index Remains In &#8216;Extreme Greed&#8217; Zone</a> </li>
</ul>
Photo via Shutterstockhsdt be

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEBI

AIRJ

HSDT

PTHS

SHLS

Helius Medical Technologies, Sunrun And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Barclays analyst Jared Shaw downgrades First Hawaiian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHB#NASDAQ">FHB</a>) from Equal-Weight to Underweight and lowers the price target from $27 to $25.

Downgrades

Price Target

Barclays Downgrades First Hawaiian to Underweight, Lowers Price Target to $25

MBAVU

Trading Halt: Halt status updated at 8:00:00 AM ET: Quotation Resumption: News and Resumption Times

T. Rowe Price Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) may be heading into a long stretch of underperformance, if the Adhishthana Cycle is anything to go by. The stock has now entered the 18th and final phase of its Adhishthana Cycle on the weekly chart, a phase that typically brings either a peak or a slump, depending on prior structure.
<h3 class="wp-block-heading">Breaking Down the Past Moves</h3>
TROW had shown strong structural alignment with the Adhishthana principles throughout much of its cycle. Particularly between Phases 10 to 12, the stock formed what&#8217;s referred to as the Adhishthana Himalayan Formation.&nbsp;
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="1002" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08084654/TROW-Himalyan-Formation-Adhishthana.png" alt="Fig.1 TROW Himalayan Formation (Source: Adhishthana.com Reports)" class="wp-image-15444" style="width:580px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08084654/TROW-Himalyan-Formation-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08084654/TROW-Himalyan-Formation-Adhishthana-300x251.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08084654/TROW-Himalyan-Formation-Adhishthana-1024x855.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08084654/TROW-Himalyan-Formation-Adhishthana-768x641.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.1 TROW Himalayan Formation (Source: Adhishthana.com Reports)</figcaption></figure>
The stock began to rally in Phase 10, signaling the start of the ascent of the formation, and ended the phase without a peak.
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">Quoting from my book: "The 18th interval is expected to be the level of peak formation; if not, then the 23rd interval. If this phase concludes without forming the peak, it is anticipated to occur in the following phases." — Adhishthana: The Principles That Govern Wealth, Time &amp; Tragedy
</blockquote>
With no peak visible in Phase 10, the stock continued upward with strong momentum into Phase 11, where it finally topped at $224.56. What followed was equally predictable within the Adhishthana context. A swift and deep correction known as the "Wrath of Ganga." This move erased much of the gains, pulling the stock back toward the origin of the rally and completing the Adhishthana Himalayan Formation with structural precision.
<h3 class="wp-block-heading">What Phase 18 Means for TROW</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="456" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08084801/TROW-Adhishthana-Weekly-Chart.png" alt="Fig.2 TROW Weekly Chart (Source: Adhishthana.com Reports)" class="wp-image-15445" style="width:837px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08084801/TROW-Adhishthana-Weekly-Chart.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08084801/TROW-Adhishthana-Weekly-Chart-300x114.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08084801/TROW-Adhishthana-Weekly-Chart-1024x389.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08084801/TROW-Adhishthana-Weekly-Chart-768x292.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.2 TROW Weekly Chart (Source: Adhishthana.com Reports)</figcaption></figure>
With the stock now in Phase 18, the outlook gets murky. Typically, a stock may hit its Nirvana (the highest point in its cycle) during this phase, but only if certain preconditions are met. In TROW&#8217;s case, the Guna Triads (Phases 14–16) lacked the necessary bullish strength, known as Satoguna in the Adhishthana model.
Without this element, the stock is unlikely to rally in its current Phase 18. Instead, TROW may spend the remainder of this phase through June 28, 2026, in a state of bearish consolidation.
<h3 class="wp-block-heading">Monthly Outlook Adds Pressure</h3>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="539" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08084829/TROW-Monthly--1024x539.png" alt="Fig.3 TROW Monthly Chart (Source: Adhishthana.com Reports)" class="wp-image-15446" style="width:668px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08084829/TROW-Monthly--1024x539.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08084829/TROW-Monthly--300x158.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08084829/TROW-Monthly--768x404.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08084829/TROW-Monthly-.png 1166w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Fig.3 TROW Monthly Chart (Source: Adhishthana.com Reports)</figcaption></figure>
Zooming out, the monthly structure adds to the caution. TROW is currently in Phase 12 on the monthly chart. Similar to the weekly timeframe, the stock has completed its Himalayan Formation here as well — but without signs of continuation.
Here's the problem: the monthly Phase 13 doesn't end until late 2029. And if momentum remains weak through weekly Phase 18, a similar multi-year sideways or downward trend could follow on the monthly scale due to a range-bound Phase 12.
<h3 class="wp-block-heading">Investor Takeaway</h3>
TROW may not be the most attractive bet in its current structure. Long-term holders should be prepared for extended weakness or sideways movement, as there's little sign of strength emerging anytime soon. Even for those considering hedging, the wide spreads in the options chain make it a tough play for retail participants. As for new investors, it's best to stay on the sidelines until the structure shifts—something that doesn't appear likely in the near term.

Equities

Technicals

Opinion

Signals

TROW

T. Rowe Price: Why Shares Could See Prolonged Underperformance

Swissmedic, the Swiss Agency for Therapeutic Products, approved Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Coartem (artemether-lumefantrine) Baby on Tuesday. This marks the first malaria medicine specifically approved for <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">newborns and young infants</a>.
The new treatment, also known as Riamet Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV).
Until now, there has been no approved malaria treatment for infants weighing less than 4.5 kilograms. They have instead been treated with formulations intended for use in older children, which may increase the risk of overdose and toxicity, the company <a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/98420ef2-16eb-4e75-812a-4f868349ce60" rel="noreferrer noopener">said</a> in a statement on Tuesday. Malaria vaccines are also not approved for the youngest babies.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44148407/fda-places-clinical-hold-on-biontechs-early-phase-trial-for-rna-based-malaria-vaccine" rel="noreferrer noopener">FDA Places Clinical Hold On BioNTech&#8217;s Early-Phase Trial For RNA-Based Malaria Vaccine</a>
Malaria, caused by a parasite and spread to humans by some mosquitoes, remains a <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40758355/malaria-may-have-killed-half-of-humans-throughout-history-now-bill-gates-has-a-breakthrough-plan-" rel="noreferrer noopener">global health concern</a>, particularly in Africa. According to the most recent WHO data, there were 263 million cases of malaria and 597,000 deaths in 2023, almost all of them in Africa. Children under 5 years old accounted for about three in four malaria deaths in the region.
Some 30 million babies are born in areas of malaria risk in Africa every year, with one large survey across West Africa reporting infections ranging between 3.4% and 18.4% in infants younger than 6 months old. However, current data on malaria in young babies is minimal, as they are rarely included in clinical trials of antimalarial agents.
Novartis plans to introduce Coartem Baby on a largely not-for-profit basis to support access to care in malaria-endemic regions. The treatment is dissolvable, including in breast milk, and has a sweet cherry flavor to aid administration to infants.
The Swissmedic approval is based on the Phase 2/3 CALINA study, which investigated a new ratio and dose of Coartem (artemether-lumefantrine) to account for metabolic differences in babies under 5 kilograms.
The treatment is indicated for infants and neonates weighing between 2 and less than 5 kilograms with acute, uncomplicated infections caused by Plasmodium falciparum or mixed infections including P. falciparum. Coartem is known by the brand name Riamet in Switzerland and some other countries.
Eight African countries also participated in the assessment process and are expected to issue rapid approvals for Coartem Baby under Swissmedic&#8217;s Marketing Authorization for Global Health Products procedure.
Novartis developed the new dose strength designed for young infants with the scientific and financial support of MMV, and as part of the PAMAfrica consortium, which is co-funded by the European &amp; Developing Countries Clinical Trials Partnership and the Swedish International Development Cooperation Agency.
Price Action: NVS is trading lower by 0.25% to $121.82 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/46166652/fda-eases-access-to-life-saving-gene-therapies-for-blood-cancers" target="_blank" rel="noreferrer noopener">FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers</a></li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

Novartis Gets Swiss Approval For First Malaria Drug For Babies

Barclays analyst Mark Devries upgrades UWM Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UWMC#NYSE">UWMC</a>) from Equal-Weight to Overweight and announces $6 price target.

Upgrades

UWMC

Barclays Upgrades UWM Holdings to Overweight, Announces $6 Price Target

Quantum computing firm&nbsp;IonQ Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) saw a price target hike from Benchmark after the company successfully raised $1 billion through an equity offering at $55.49 per share, a notable 25% premium to the closing price last Thursday.
What Happened: The equity offering is likely to bring IonQ&#8217;s pro-forma cash to an estimated $1.68 billion, accelerating the company&#8217;s commercialization efforts. Benchmark analyst David Williams has reiterated a Buy rating on IonQ shares and increased his price target from $50 to $55, expressing confidence in IonQ&#8217;s potential in the quantum computing market, <a href="https://www.barrons.com/articles/ionq-stock-offering-buy-rating-be632dc5?">reported </a>Barrons.
The price target was raised following a fireside chat between Benchmark analysts and IonQ CEO Niccolo de Masi and CFO Thomas Kramer, which strengthened the firm's optimistic view of the company.
Williams highlighted IonQ&#8217;s unique approach, which includes &#8220;positioning itself as a leader in both quantum computing and the increasingly critical field of quantum networking.&#8221; He also noted the company&#8217;s plans to gradually scale up its quantum machines, expressing confidence in its technical roadmap.
The company&#8217;s CEO, Niccolo de Masi, has underscored IonQ&#8217;s focus on quantum networking as a more feasible approach to constructing larger quantum computers. 
IonQ is widely seen as having the most commercially focused and differentiated business model and market strategy in the quantum computing space. The company has set bold targets, aiming to expand from 256 physical qubits in 2026 to 2 million physical qubits and 80,000 logical qubits by 2030. Williams says its highly commercial and differentiated strategy positions the company well as the industry evolves.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/tech/25/07/46272105/jack-dorsey-unveils-bitchat-a-decentralized-bluetooth-powered-server-free-messaging-service" target="_blank" rel="noreferrer noopener">Jack Dorsey Unveils &#8216;Bitchat,&#8217; A Decentralized, Bluetooth-Powered, Server-Free Messaging Service</a>
Why It Matters: The quantum computing industry is gaining significant investor attention due to its long-term economic potential, with IonQ being a standout frontrunner, <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46229237/cash-rich-ionq-to-capture-20-of-quantum-market-by-2035-analyst">according to</a> Cantor Fitzgerald analyst Troy Jensen. Despite its nascent stage, the industry is seeing substantial stock valuations, with IonQ expected to capture 20% of the quantum market by 2035.
IonQ&#8217;s stock has been on a surge, with the company&#8217;s commitment to building a quantum ecosystem in Texas, following the passage of the Texas Quantum Initiative,&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/25/06/46175752/ionq-stock-is-surging-monday-whats-driving-the-rally">driving the rally</a>.
Additionally, the company&#8217;s recent scientific achievements—such as advancements in protein folding and particle physics in partnership with the U.S. Department of Defense—highlight the company&#8217;s growing potential in the quantum computing space.
Benzinga Edge Stock Rankings show that IonQ stock had a strong price trend over the short, medium and long term. Its momentum ranking was strong at 9the 9th percentile, whereas its value ranking was poor at the 3rd percentile; the details of other metrics are available <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a>.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46232263/d-wave-surges-1326-whats-driving-quantum-computings-newest-star">D-Wave Surges 1,326%: What&#8217;s Driving Quantum Computing&#8217;s Newest Star? </a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

IONQ

This Quantum Computing Stock Just Raised $1 Billion — And Analyst Says It's Only Getting Started

MBAV

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

RLYB

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

<ul>
<li>ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into the urine (proteinuria) and chronic kidney disease.</li>
<li>Despite being treated with standard-of-care renal drug therapy (ACEi, SGLT2, statin, and ezetimibe), the patient authorized by FDA to receive VAR 200 is showing continued kidney disease progression. Because her kidney biopsy demonstrated lipid deposition, the treating physician, Dr. Alessia Fornoni, hypothesized that VAR 200 has potential to alleviate lipid accumulation, proteinuria, and disease progression. This is based on VAR 200's consistent results across preclinical studies in three different models of kidney disease, and supporting HPβCD clinical data in patients with lysosomal storage and protein deposition disorders, such as Niemann-Pick disease type C.</li>
<li>VAR 200, currently in a phase 2a clinical trial for diabetic kidney disease (DKD), was designed to passively and actively reduce renal lipid accumulation to protect against renal injury and fibrosis and improve kidney function.</li>
</ul>
WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>, "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, is pleased to provide regulatory and product support for FDA-authorized Emergency Compassionate Use of Cholesterol Efflux Mediator&#x2122;&nbsp;VAR 200 in a patient with ApoCII amyloidosis. Emergency Compassionate Use, also called Emergency Expanded Access, is a pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational drug for treatment outside of clinical trials when enrollment criteria are not met or there are no comparable or satisfactory alternative therapy options.
The patient with ApoCII amyloidosis will receive treatment at the University of Miami Peggy and Harold Katz Family Drug Discovery Center under the care of the Center Director, Dr. Alessia Fornoni, Professor of Medicine, University of Miami Miller School of Medicine, and VAR 200 inventor. VAR 200 treatment and monitoring will follow the protocol of the ongoing DKD clinical trial, VAR200-0301

ZVSA

ZyVersa Therapeutics Provides Regulatory And Product Support For FDA-Authorized Emergency Compassionate Use Of Cholesterol Efflux Mediator VAR 200 In ApoCII Amyloidosis Patient

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Keybanc analyst Sophie Karp upgraded the rating for Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from Underweight to Sector Weight. Sunrun shares closed at $11.11 on Monday. <a href="https://www.benzinga.com/quote/run/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dumoulin-Smith upgraded Southwest Gas Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWX#NYSE">SWX</a>) from Hold to Buy and raised the price target from $74 to $82. Southwest Gas shares closed at $72.88 on Monday. <a href="https://www.benzinga.com/quote/swx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Sophie Karp upgraded SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from Underweight to Sector Weight. SolarEdge shares closed at $26.43 on Monday. <a href="https://www.benzinga.com/quote/sedg/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert upgraded Artelo Biosciences, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ARTL#NASDAQ"> ARTL</a>) from Hold to Buy and announced a $20 price target. Artelo Biosciences shares closed at $14.32 on Monday. <a href="https://www.benzinga.com/quote/artl/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying SWX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/SWX/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08074652/image-77-1024x583.png" alt="" class="wp-image-976369" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08074652/image-77-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08074652/image-77-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08074652/image-77-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08074652/image-77.png 1136w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46289573/trump-tariffs-sink-dow-over-400-points-investor-sentiment-declines-but-fear-greed-index-remains-in-extreme-greed-zone">Trump Tariffs Sink Dow Over 400 Points: Investor Sentiment Declines, But Fear &amp; Greed Index Remains In &#8216;Extreme Greed&#8217; Zone</a> </li>
</ul>
Photo via Shutterstock

OSCR

VOYG

This Southwest Gas Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday

Barclays analyst Terry Ma downgrades BrightSpire Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRSP#NYSE">BRSP</a>) from Equal-Weight to Underweight and lowers the price target from $7 to $5.

Comments

Chime Financial

Intérêt court

Chime Financial (NASDAQ:CHYM) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL